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To estimate cut-off points and to establish response criteria for the Hospital Universitario La
Princesa Index (HUPI) in patients with chronic polyarthritis.
Methods
Two cohorts, one of early arthritis (Princesa Early Arthritis Register Longitudinal [PEARL]
study) and other of long-term rheumatoid arthritis (Estudio de la Morbilidad y Expresión
Clínica de la Artritis Reumatoide [EMECAR]) including altogether 1200 patients were used
to determine cut-off values for remission, and for low, moderate and high activity through
receiver operating curve (ROC) analysis. The areas under ROC (AUC) were compared to
those of validated indexes (SDAI, CDAI, DAS28). ROC analysis was also applied to estab-
lish minimal and relevant clinical improvement for HUPI.
Results
The best cut-off points for HUPI are 2, 5 and 9, classifying RA activity as remission if2,
low disease activity if >2 and5), moderate if >5 and <9 and high if9. HUPI’s AUC to dis-
criminate between low-moderate activity was 0.909 and between moderate-high activity
0.887. DAS28’s AUCs were 0.887 and 0.846, respectively; both indices had higher accu-
racy than SDAI (AUCs: 0.832 and 0.756) and CDAI (AUCs: 0.789 and 0.728). HUPI discrim-
inates remission better than DAS28-ESR in early arthritis, but similarly to SDAI. The HUPI
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cut-off for minimal clinical improvement was established at 2 and for relevant clinical
improvement at 4. Response criteria were established based on these cut-off values.
Conclusions
The cut-offs proposed for HUPI perform adequately in patients with either early or long term
arthritis.
Introduction
The treat to target (T2T) strategy has improved the outcome of rheumatoid arthritis (RA) and
therefore has been included in established RA guidelines [1,2]. In relation to this strategy, there
is substantial agreement on considering remission, or low disease activity, as the therapeutic
objective for most patients with RA [1,2]. However, DAS28 and SDAI, the most widely-used
indices for defining these targets, have several biases that may interfere with their accuracy [3–
6]. DAS28 has the additional inconvenient that its values differ when it is calculated with either
erytrosedimentation rate (ESR) or C-reactive protein (CRP) [7,8]. Furthermore, both DAS28
and SDAI have a gender bias derived from the larger number of tender joints and of ESR values
in women compared to men [5,9,10]. To overcome these issues, we developed the Hospital
Universitario La Princesa Index (HUPI), an index for the assessment of disease activity in
chronic polyarthritis that includes the same domains as in DAS28 and SDAI but corrected by
gender and easier to calculate than the DAS28 (Table 1) [6]. Moreover, it can be calculated
with either CRP, or ESR or both. Fig 1 shows how the interchangeability of values is better with
HUPI than with DAS28. This may be of special interest in observational studies to avoid miss-
ing data. HUPI has demonstrated high accuracy, feasibility and sensitivity to change, even
superior to those of DAS28 and SDAI [6]. However, to be useful both in daily clinical practice
and clinical trials it is necessary to define cut-off points that allow establishing different levels
of disease activity, as well as response criteria, such as those based on DAS28 [11].
The objectives of this study were 1) to establish cut-off points for HUPI able to discriminate
between activity levels both in early arthritis and in long-term RA populations; 2) to establish
response criteria based on HUPI; and 3) to compare the accuracy and discriminant ability to
that of widely-used indices.
Methods
Patients
This is a validation study with repeated measures for which we used data obtained from two
cohorts. HUPI was developed and validated in a mixed population of early RA and undifferen-
tiated arthritis (UA) patients, the Princesa Early Arthritis Register Longitudinal study
(PEARL) cohort [6], which we now use also to define cut-offs. In order to determine whether
HUPI and its cut-offs are valid in long-term RA we added the data from the Estudio de la Mor-
bilidad y Expresión Clínica de la Artritis Reumatoide (EMECAR) cohort [12].
The research carried out in PEARL and EMECAR is in compliance with Helsinki Declara-
tion. The Ethics Committee for Clinical Research at Hospital Universitario de La Princesa
reviewed and approved both protocols, and all patients included in both studies signed an
informed consent form.
HUPI Cut-Off Points
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Table 1. Scoring of the variables used to calculate HUPI.
0 1 2 3
Tender joints/28 ♀ 0 1–2 3–6 >6
♂ 0 1 2–3 >3
Swollen joints/28 0 1–2 3–4 >4
GDA-Patient (0–100) 0–15 16–30 31–50 >50
C-reactive protein (mg/dl) 0.1 0.11–0.8 0.81–1.5 >1.5
Erythrosedimentation rate ♀ 0–15 16–20 21–30 >30
♂ 0–10 11–15 16–20 >20
GDA: global disease assessment. HUPI is calculated as the sum of four variables (graded 0–3): 28 tender and swollen joint counts, global disease
assessment by physician and acute phase reactants (the average score value of ESR and CRP must be used if both acute phase reactants are considered).
The score of these variables was based in their quartile distribution in the population used to describe the index [6].
doi:10.1371/journal.pone.0161727.t001
Fig 1. Interchangeability of disease activity score values calculated with erytrosedimentation rate (ESR) or C-reactive protein
(CRP) is more accurate with HUPI than with DAS28.Data are shown as percent of visits with a given difference between calculated
scores: A) DAS28 calculated with ESR (DAS28_ESR) minus DAS28 calculated with CRP (DAS28_CRP), B) HUPI calculated with ESR
(HUPI_ESR) minus HUPI calculated with CRP (HUPI_CRP), C) HUPI calculated with both acute phase reactants (HUPI) minus
HUPI_ESR, and D) HUPI minus HUPI_CRP. Vertical red lines show the percent of visits where the scores from both pairs was equal (Δ =
0). In the case of DAS28 a difference of ±0.25 was considered equal to null.
doi:10.1371/journal.pone.0161727.g001
HUPI Cut-Off Points
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The Princesa Early Arthritis Register Longitudinal (PEARL) cohort
PEARL includes patients recruited from the early arthritis clinic of Hospital Universitario La
Princesa, Madrid (Spain). Patients with a suspicion of arthritis of less than a year since symp-
tom onset are referred to this clinic. Patients diagnosed with gout, septic or viral arthritis, oste-
oarthritis, spondyloarthropathies or connective tissue diseases during the first 2 years of
follow-up are excluded from the cohort. Therefore, for this specific analysis, only patients ful-
filling the 1987 ACR RA criteria [13] or with chronic undifferentiated arthritis (UA) were
included. The clinical protocol includes five visits during a follow-up period of 5 years (base-
line, 6, 12, 24 and 60 months) in which demographic, clinical, therapeutic, and laboratory data
as well as biologic samples are collected. With the information collected it is possible to esti-
mate the value of the following disease activity indexes: DAS28-ESR [14], DAS28-CRP (calcu-
lated as described in http://www.das-score.nl), SDAI [15], CDAI [15] and HUPI [6]. More
detailed information about the protocol has been described previously [16].
The EMECAR cohort
EMECAR was a prospective longitudinal cohort of prevalent RA patients selected by random
sampling in 34 Rheumatology Units from Spain. The follow-up took place from November
1999 to December 2004. EMECAR database includes the required information to calculate
DAS28-ESR, DAS28-CRP and HUPI, but not SDAI or CDAI since global disease assessment
by physician was not collected. Remission was defined in EMECAR by the Pinal’s criteria [17].
A more detailed description of the EMECAR cohort has been published previously [12].
Definition of low, moderate and high disease activity
We used two definitions, depending on the cohort.
Low, moderate and high disease activity levels were established in a subset of PEARL as pre-
viously reported [18]. Six experienced rheumatologists (AMO, ET, IC, SC, AG-V and IG-A)
categorized the level of disease activity into low-moderate-high at each visit based on the fol-
lowing information: 28 tender and swollen joint counts, global disease assessment by patient in
a 0 to 100 mm scale, Health Assessment Questionnaire, ESR, and CRP. The assessment was ret-
rospective and therefore, the physicians could not physically examine the patients. In addition,
they were blinded to the global disease assessment by physician obtained on a 0 to 10 visual
analog scale at each visit.
In EMECAR, low, moderate and high disease activity level were defined by the DAS28-ESR
classical cut-offs (2.6, 3.2 and 5.1) [14].
Criteria to define remission
Considering that at present there is no definitive consensus on a best definition for remission
and the differences in data collection at the two cohorts, we used 4 operational definitions to
estimate this cut-off point for HUPI: 1) by the consensus of the 6 experienced rheumatologists
in the subpopulation of PEARL; 2) by the ACR/EULAR remission criteria according to SDAI
(<3.3); 3) by the ACR/EULAR remission criteria according to Boolean criteria [19]; and by the
criteria by Pinals et al [17].
Estimation of cut-off points
Receiver operating characteristic (ROC) analysis was performed using the “roctab” command
of Stata 12.11 for Windows (StataCorp LP, College Station, TX, USA). Each cut-off point was
selected on the basis of the best trade-off values between sensitivity and specificity. ROC curves
HUPI Cut-Off Points
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were also obtained with the “roctab” command of Stata, using the “graph” option. To estimate
whether the differences in the area under the curve (AUC) between the indices were statisti-
cally significant, we used the Stata “roccomp” command that provides a test for the equality of
the AUCs using an algorithm described by DeLong et al.[20]. Statistical significance was
accepted if the p value was lower than 0.05.
Estimation of minimal and relevant clinical improvement for HUPI
PEARL patients whose ΔDAS28-ESR between baseline and 6 months follow-up visits was0.6
were considered to experience, at least, a minimal clinical improvement. Those patients whose
ΔDAS28-ESR was1.2 were considered to experience a relevant clinical improvement.
The best value for minimal or relevant clinical improvement for HUPI was selected on the
basis of the best trade-off values between sensitivity and specificity from the respective ROC
curves as described above for cut-off points to separate disease activity levels.
Results
Patients’ characteristics
We studied data from 1547 visits of 403 patients included in PEARL study and 2880 visits
belonging to 789 patients from EMECAR. Since the former is an early arthritis register and the
later a prevalent RA cohort, patients from PEARL study were on average 6 years younger than
EMECAR patients (Table 2). Accordingly, at baseline, disease duration was longer in EMECAR
Table 2. Baseline characteristics of patients and distribution of disease activity level in all visits from
studies PEARL and EMECAR.
EMECAR PEARL
Number of patients 789 403
Age, m ± SD 61 ± 13 55 ±16
Female gender, n (%) 568 (72) 322 (80)
Disease duration (years; IQR) 8.7 [4.1–12.6] 0.5 [0.3–0.7]
RA / UA, n (%) 789 (100) / - 280 (69.5) / 123 (30.5)
RF positive, n (%) 592 (75) 208 (51.6)
DAS28-ESR, mean ± SD 4.2 ± 1.4 4.5 ± 1.5
DAS28-CRP, mean ± SD - 4.0 ± 1.4
SDAI, median [IQR] - 17.0 [8.9–32.1]
CDAI, median [IQR] - 14.8 [8.1–30.1]
HUPI, mean ± SD 6.5 ± 2.9 7.0 ± 3.2
Visits 2,880 1,547
Disease activity level defined by DAS28-ESR. N (%)
Remission 560 (19.4%) 438 (28.3%)
Low 426 (14.8%) 241 (15.6%)
Moderate 1,303 (45.2%) 568 (36.7%)
High 526 (18.3%) 261 (16.9%)
No DAS28-ESR available 65 (2.3%) 39 (2.5%)
EMECAR: Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide; PEARL: Princesa Early
Arthritis Register Longitudinal; IQR: interquartile range; RA: rheumatoid arthritis; UA: undifferentiated
arthritis; RF: rheumatoid factor; DAS28-ESR: disease activity score calculated with erythrosedimentation
rate; DAS28-CRP: disease activity score calculated with C-reactive protein; SD: standard deviation; SDAI:
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patients but slightly higher disease activity was observed in patients from PEARL study
(Table 2), since these patients were untreated at baseline visit whereas EMECAR patients were
under treatment when enrolled at the cohort. Table 2 also shows the number of visits in which
the patients were at remission, low, moderate or high disease activity (defined by DAS28-ESR
cut-off points: 2.6, 3.2, 5.1).
Cut-off points for low/moderate and moderate/high disease activity
The best threshold value of the HUPI to discriminate between low and moderate disease activ-
ity was 5 (Table 3). As it is shown in Fig 2 (upper panels), there were no significant differences
between area under ROC curves of HUPI and the two versions of DAS28. However, the AUC
of HUPI was significantly greater than those of SDAI (p = 0.0002) and CDAI (p<0.0001). Like-
wise, both DAS28 versions (ESR and CRP) showed higher ROC curves areas than SDAI and
CDAI (p<0.0001).
Remission cut-off point for HUPI
Table 4 summarizes the best cut-off points for remission considering the different populations
and definitions described under Methods. In view of all these results, we decided to choose 2 as
cut-off for remission in HUPI.
In order to determine whether HUPI is more accurate than DAS28 or SDAI for estimating
remission, we compared DAS28 and HUPI in EMECAR and PEARL with all previous defini-
tions and SDAI and HUPI in PEARL with rheumatologist assessment and Boolean based
ACR/EULAR remission criteria. As it is shown in Fig 3, HUPI is, depending on definition of
remission, as accurate as DAS28 (A and B panels) or significantly superior (ACR/EULAR
remission definitions at C and D panels). HUPI was significantly better than SDAI when using
the classification of remission by experienced rheumatologists (Fig 3A) but worse than SDAI
when using the 2011 Boolean definition of remission (Fig 3C).
Fig 4A shows how cut-off points to define remission, low, moderate and high disease activ-
ity are distributed along the range of values of DAS28, SDAI and HUPI. Interestingly, the dis-
tribution of the cut-off points on the HUPI is more homogeneous in HUPI than in the other
scales.
Response criteria using HUPI
Aminimal clinical improvement in HUPI, corresponding to a 0.6 point improvement in
DAS28, was 2 (Sensitivity [Se] 73%, Specificity [Sp] 84%; Positive likelihood ratio [LR+] 3.15,
LR- 0.21). A relevant clinical improvement in HUPI, corresponding to a 1.2 points improve-
ment in DAS28, was 4 (Se 65%, Sp 90%; LR+ 6.22, LR– 0.39). Considering the cut-off points
Table 3. Cut-offs for low-moderate andmoderate-high disease activity in HUPI.
Population Disease activity AUC Cut-off point Se Sp LR + LR -
PEARL Low—Moderate 0.909 >5 72% 89% 3.18 0.15
EMECAR Low—Moderate 0.945 >5 81% 92% 10.03 0.21
PEARL Moderate–High 0.887 9 72% 90% 3.24 0.14
EMECAR Moderate–High 0.937 9 70% 93% 10.45 0.32
HUPI: Hospital Universitario Princesa Index; AUC: area under curve; Se, sensitivity; Sp, specificity; LR: likelihood ratio EMECAR: Estudio de la Morbilidad y
Expresión Clínica de la Artritis Reumatoide; PEARL: Princesa Early Arthritis Register Longitudinal.
doi:10.1371/journal.pone.0161727.t003
HUPI Cut-Off Points
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and the estimation for relevant improvement for HUPI, Fig 4B shows how to classify the
response into none, moderate or good by using the HUPI.
Discussion
The assessment of disease activity in RA through composite indexes, such as DAS28 or SDAI,
has been a cornerstone in clinical research, translational research and daily clinical practice.
However, several concerns affect both indexes: a difficult calculation of DAS28, gender bias,
left skewed distribution of their values leading to low sensitivity to change, especially with
SDAI [4–6,21]. All these problems led us to develop HUPI, with the hope that it could be useful
in clinical and translational research and probably in daily clinical practice since it is easy to
calculate without calculator. However, to be useful in the current T2T strategies we needed spe-
cific cut-off values to determine the common targets (clinical remission or low disease activity)
accepted at present, and this study has established them.
In addition, the present study suggests that HUPI is more accurate than SDAI to discrimi-
nate low-moderate disease activity. This is an important landmark of HUPI since this level of
Fig 2. HUPI and DAS28 discriminate low-moderate andmoderate-high disease activity better than SDAI and CDAI.Receiver operating curves were
plot using the “roctab” command of STATA, with the option graph. Data obtained from the PEARL cohort. The best cut-off point to discriminate between
moderate and high disease activity was 9 (Table 3). The AUC of HUPI was systematically larger than those from the other indices (Fig 1 lower panels),
although differences were only significant with SDAI (p = 0.0004) and CDAI (p = 0.0001).
doi:10.1371/journal.pone.0161727.g002
HUPI Cut-Off Points
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activity is commonly used to prescribe biological therapy [1,2] as well as to initiate tapering of
kind of treatment [22].
Furthermore, depending on the definition, HUPI discriminates clinical remission better
than DAS28. This may be due to the fact that HUPI corrects for gender and for extreme values,
both accepted as interfering with the definition of remission [23].
Table 4. Cut-off points for remission in HUPI.
Population Remission definition AUC Cut-off point Se Sp LR + LR -
PEARL Rheumatologists consensus 0.962 2 84% 92% 5.74 0.09
PEARL ACR/EULAR SDAI<3.3 0.976 2 90% 93% 9.66 0.07
PEARL ACR/EULAR Boolean 0.949 <2 88% 92% 7.57 0.09
EMECAR Pinals criteria 0.890 2 49% 95% 1.86 0.11
HUPI: Hospital Universitario Princesa Index; AUC: area under curve; Se: sensitivity; Sp: specificity; LR: likelihood ratio; PEARL: Princesa Early Arthritis
Register Longitudinal; EMECAR: Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide; ACR: American College of Rheumatology; EULAR:
European League Against Rheumatism; SDAI: simplified disease activity index.
doi:10.1371/journal.pone.0161727.t004
Fig 3. Receiver operating curves (ROC) for HUPI, SDAI and DAS28 to discriminate remission. A) Remission defined by rheumatologist consensus in
PEARL population. B) Remission defined by Pinals criteria in EMECAR population. C) Remission defined by ACR/EULAR boolean criteria in PEARL
population. D) Remission defined by ACR/EULAR SDAI<3.3 criteria in PEARL population. Receiver operating curves were plot using the “roccomp”
command of STATA, with the option graph. This command also tests the equality of ROC areas.
doi:10.1371/journal.pone.0161727.g003
HUPI Cut-Off Points
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Fig 4. Cut-off points and response criteria for HUPI. A) Comparison of cut-off points’ distribution along HUPI, DAS28 and
SDAI’s range of values. B) Response criteria using HUPI based on its cut-off values for low, moderate and high disease, as
HUPI Cut-Off Points
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One of the main limitations of this study is the absence of real gold standards for evaluating
disease activity. This was the reason leading to the use of several definitions of remission and
different ways of defining low, moderate and high disease activity either in PEARL and EME-
CAR. Nevertheless, the results in both populations were quite concordant, which is reassuring
on the validity of the HUPI. Another limitation of HUPI is that it may suffer from a ceiling
effect in patients with very high disease activity. It is possible that in clinical trials in which
such kind of patients is preferentially included sensitivity to change might be more difficult to
demonstrate.
We are aware that implementation of HUPI will be difficult since DAS28 and SDAI are
deeply accepted by rheumatologists. However, we provide this information convinced that
HUPI will be useful to scientists involved in RA clinical and translational research. It would be
especially interesting when needing complex multivariable analysis since HUPI suffers from
less biases than DAS28 and SDAI and its values show a normal distribution.
Finally, further validation of the index, its cut-offs and response criteria will be needed in
different cohorts, either in early and long term RA populations, as well as in patients with very
high disease activity from clinical trials. Of special interest will be to study whether HUPI or
current validated indexes explain better radiological progression or biological processes.
In summary, we have estimated the most adequate cut-offs for the HUPI to define levels of
activity in RA (low-moderate-high and remission), which are stable in early and long-term
populations, and found that HUPI is at least as good as widely established indices.
Supporting Information
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